Bolt Biotherapeutics Inc [BOLT] stock is trading at $1.40, up 14.75%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BOLT shares have gain 20.69% over the last week, with a monthly amount glided 17.65%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 21, March 2024, Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update. In a post published today on Yahoo Finance, – BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balance of $128.6 million as of December 31, 2023, anticipated to fund key milestones through late 2025.
From an analyst’s perspective:
Bolt Biotherapeutics Inc [NASDAQ: BOLT] stock has seen the most recent analyst activity on January 06, 2022, when Morgan Stanley downgraded its rating to a Equal-Weight. Previously, SVB Leerink started tracking the stock with Outperform rating on March 02, 2021, and set its price target to $36. On March 02, 2021, Stifel initiated with a Buy rating and assigned a price target of $40 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $45 on March 02, 2021. Guggenheim initiated its recommendation with a Buy and recommended $42 as its price target on March 02, 2021.
Bolt Biotherapeutics Inc [BOLT] stock has fluctuated between $0.84 and $2.03 over the past year. Bolt Biotherapeutics Inc [NASDAQ: BOLT] shares were valued at $1.40 at the most recent close of the market.
Analyzing the BOLT fundamentals
Bolt Biotherapeutics Inc [NASDAQ:BOLT] reported sales of 7.88M for the trailing twelve months, which represents a growth of 48.05%. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at -9.67%, Pretax Profit Margin comes in at -8.79%, and Net Profit Margin reading is -8.6%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.5 and Total Capital is -0.55. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2583 points at the first support level, and at 1.1167 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5033, and for the 2nd resistance point, it is at 1.6067.
Bolt Biotherapeutics Inc [BOLT] reported earnings per share of -$0.47 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.48/share, meaning a difference of $0.01 and a surprise factor of 2.10%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.43 per share as compared to estimates of -$0.5 per share, a difference of $0.07 representing a surprise of 14.00%.
Ratios To Look Out For
For context, Bolt Biotherapeutics Inc’s Current Ratio is 5.16. Further, the Quick Ratio stands at 5.16, while the Cash Ratio is 0.53. Considering the valuation of this stock, the price to sales ratio is 6.77, the price to book ratio is 0.47.
Transactions by insiders
Recent insider trading involved Quinn William P., Chief Financial Officer, that happened on Dec 12 ’23 when 7500.0 shares were purchased. Chief Financial Officer, Quinn William P. completed a deal on Dec 06 ’23 to buy 2500.0 shares. Meanwhile, Director ENGLEMAN EDGAR sold 0.12 million shares on Nov 30 ’23.
